Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast
Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 billion in revenue for Q4 2024, compared to the consensus estimate of $13.97 billion.
Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far exceeding the average of 3.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
GlobalData on MSN1d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.
Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback